Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Rating of "Buy" from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has earned an average recommendation of "Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $85.25.

GPCR has been the subject of a number of research reports. JMP Securities reissued a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Friday, May 10th. Lifesci Capital reissued an "outperform" rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 17th. JPMorgan Chase & Co. began coverage on shares of Structure Therapeutics in a report on Tuesday, May 21st. They set an "overweight" rating and a $65.00 price target for the company. Finally, BMO Capital Markets boosted their price objective on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an "outperform" rating in a research report on Friday, June 7th.

Structure Therapeutics Stock Performance

GPCR traded down $1.18 on Friday, reaching $45.57. The company had a trading volume of 711,883 shares, compared to its average volume of 1,816,507. The stock has a market cap of $2.12 billion and a P/E ratio of -59.18. Structure Therapeutics has a fifty-two week low of $25.57 and a fifty-two week high of $75.02. The company's fifty day moving average is $41.29 and its 200 day moving average is $42.19.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.02. On average, sell-side analysts expect that Structure Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Boxer Capital LLC acquired a new stake in Structure Therapeutics in the fourth quarter valued at $16,304,000. Federated Hermes Inc. raised its position in shares of Structure Therapeutics by 104.2% during the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company's stock worth $92,411,000 after acquiring an additional 1,157,006 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Structure Therapeutics by 133.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company's stock worth $95,107,000 after acquiring an additional 1,333,333 shares during the period. Octagon Capital Advisors LP bought a new stake in Structure Therapeutics in the fourth quarter valued at approximately $16,875,000. Finally, Capital International Investors acquired a new stake in Structure Therapeutics during the 4th quarter valued at approximately $34,647,000. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.